Nowadays, only four drugs are approved for the treatment of Alzheimer’s disease: three acetylcholinesterase inhibitors (donepezil, galantamine, and rivastigmine) and memantine, an antagonist of N-methyl-D-aspartate (NMDA) receptors [10]. This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.